Genet H Zemede

US Patent:

7414105, Aug 19, 2008

Filed:

Oct 27, 2005

Appl. No.:

11/261157

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Guy Lalonde - Woodside CA, US
Peter J. Schatz - Cupertino CA, US
David Tumelty - Sunnyvale CA, US
Balu Palani - Cupertino CA, US
Genet Zemede - Santa Clara CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A01N 43/40
A61K 38/00

US Classification:

530323, 514 9, 930 90

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

7528104, May 5, 2009

Filed:

May 12, 2004

Appl. No.:

10/555868

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Guy Lalonde - Woodside CA, US
Peter J. Schatz - Cupertino CA, US
David Tumelty - Sunnyvale CA, US
Balu Palani - Cupertino CA, US
Genet Zemede - Santa Clara CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A01N 43/40
A61K 38/00

US Classification:

514 2, 514 12, 514 13, 514 14, 530323, 530324, 530326, 530327, 5303882, 530402

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

7855175, Dec 21, 2010

Filed:

Jul 11, 2008

Appl. No.:

12/171610

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Guy Lalonde - Woodside CA, US
Peter J. Schatz - Cupertino CA, US
David Tumelty - San Diego CA, US
Palani Balu - Cupertino CA, US
Genet Zemede - San Jose CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/00
A61K 51/00

US Classification:

514 2, 530300, 930 90, 424 141

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

8304391, Nov 6, 2012

Filed:

Mar 17, 2009

Appl. No.:

12/405599

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Guy Lalonde - Woodside CA, US
Peter J. Schatz - Cupertino CA, US
David Tumelty - San Diego CA, US
Balu Palani - Cupertino CA, US
Genet Zemede - San Jose CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16
A61K 38/19

US Classification:

514 214, 514 79, 514 134, 514 135, 514 213

Abstract:

Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20050137329, Jun 23, 2005

Filed:

May 12, 2004

Appl. No.:

10/844968

Inventors:

Christopher Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Guy Lalonde - Woodside CA, US
Peter Schatz - Cupertino CA, US
David Tumelty - Sunnyvale CA, US
Balu Palani - Cupertino CA, US
Genet Zemede - Santa Clara CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K038/12
C08G063/48
C08G063/91

US Classification:

525054100, 530317000, 424078300, 514009000

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20070203066, Aug 30, 2007

Filed:

Dec 8, 2006

Appl. No.:

11/636353

Inventors:

Christopher Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - Santa Clara CA, US
Yvonne Angell - San Jose CA, US
Brian Frederick - Ben Lomond CA, US
Caiding Xu - San Jose CA, US

International Classification:

A61K 38/10
A61K 38/08
C07K 7/08
C07K 7/06

US Classification:

514012000, 514013000, 514014000, 514015000, 514016000, 530326000, 530328000, 530327000, 530329000

Abstract:

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

US Patent:

20080108564, May 8, 2008

Filed:

Apr 13, 2007

Appl. No.:

11/735106

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
Yaohua S. Dong - San Francisco CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Brian T. Frederick - Ben Lomond CA, US
Anjan Chakrabarti - Gurgaon, IN
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
Nicholas C. Wrighton - Winchester MA, US
William J. Dower - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16
C07K 7/06
C07K 7/08
C07K 14/00
A61P 37/00
A61P 35/00
A61P 7/00
A61K 38/08
A61K 38/10

US Classification:

514 12, 530326, 530327, 530324, 530328, 514 13, 514 14, 514 16

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20090005292, Jan 1, 2009

Filed:

Nov 11, 2005

Appl. No.:

11/718998

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
William J. Dower - Menlo Park CA, US
Anjan Chakrabarti - Gurgaon, IN
Yaohua S. Dong - San Francisco CA, US
Brian T. Frederick - Ben Lomond CA, US
Nicholas C. Wrighton - Winchester MA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

A61K 38/02
C07K 2/00
A61P 7/00
A61P 35/00
A61P 37/00

US Classification:

514 2, 530350

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.